Navigation Links
Reportlinker Adds Therapeutics for Immune System Disorders
Date:3/24/2011

NEW YORK, March 24, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Therapeutics for Immune System Disorders

http://www.reportlinker.com/p0461662/Therapeutics-for-Immune-System-Disorders.html

In 2010, the global market for drugs for the treatment of immune disease was estimated to be approximately $72.2 billion.  The market size is forecast to grow at a compound annual growth rate (CAGR) of 2.6% to reach $82.2 billion by 2015.  

The market size of immunomodulators in 2010 is estimated to be $62.8 billion, accounting for 86.9% of the overall market. The market for immunomodulators is expected to grow by a compound annual growth rate (CAGR) of 3.4% to reach $74.1 billion by 2015, accounting for 90.2% of the market.

The demand for symptom–treating drugs is declining as advancements in immunology and life sciences help to target the underlying causes of the diseases. The market size of symptom treating diseases is expected to decline at a compound annual growth rate (CAGR) of –3.1% from $9.4 billion in 2010 to $8.1 billion in 2015.  

INTRODUCTION 

STUDY GOAL AND OBJECTIVES

This in–depth study examines recent commercial developments in immune disease treatments. There has been an explosion in knowledge concerning the immune system, and tremendous advancements in disease diagnosis and therapies with novel approaches – predominantly biologic–based treatments – replacing the traditional methods where emphasis was to treat the symptoms in order to improve the quality of life of the patient rather than treating the underlying cause of a disease. Over the past decade this new approach to immune disease has resulted in a wealth of new drugs and procedures that selectively target the causes of immune disease. This report forecasts that this trend will continue and the worldwide market for drugs that treat immune diseases will grow from an estimated $72.2 billion in 2010 to $82.2 billion by 2015. These diseases represent some of the largest market opportunities for pharmaceutical and biotechnology companies since they are common and chronic and historic treatments have been largely ineffective. The study examines the current market for the treatment of immune disease and then projects the effects of new technologies upon this market. It contains detailed analysis and provides market forecasts for the period of 2010 through 2015 and profiles the major companies involved in treating immune disease.

This report also analyzes various regulatory and market trends that will impact major immune disease segments during the forecast period. Challenges in the areas of technology and therapy are analyzed in detail and how these will be translated into important market trends and future business strategies are studied in depth and presented in the report. Finally, analysis of technology trends has been presented in the report, identifying how the most prevalent technologies in the market have changed over the past decade with the advent of biologics and future growth trends.

REASONS FOR DOING THE STUDY

BCC published a comprehensive report on the same topic in 2003 (BIO025C New Treatments and Advances in Immune Diseases). The emerging trends identified in 2003 have become more established during the past 7 years. Moreover, new trends are emerging in terms of advanced technologies and business strategies resulting in novel business models. The role of the biotechnology industry in the pharmaceutical market has become more prominent, which is strongly reflected in the immune disease sector. Based on these observations, it seems to be an appropriate time to take a look into the industry and assess the new trends and the direction the industry is taking.  

INTENDED AUDIENCE

This report offers a broad, yet detailed, overview of immune disease and the drugs that treat immune disease. Pharmaceutical and biotechnology companies working in the field will find the report useful in that it provides an unbiased assessment of the market potential of this field. In addition, the report provides an explanation of both the technology and the market effects of various new developments that the field is facing such as new biologic targets that play key roles in different immune diseases; drugs with novel methods of delivery offering a leap in convenience and efficacy; regulatory restrictions that affect the sales of blockbuster drugs; and several other challenges in the international markets and the strategies adopted to deal with them.   Investors will find the report particularly interesting since it analyzes the future potentials of major players and products in the field in a neutral manner. 

SCOPE OF REPORT

This study surveys the market for small–molecules and biologic therapies for diseases caused by disorders of the immune system: therapies covered are either already used or will be used as medicine within the next 5 years. Promising drugs in the early stages of development are analyzed, but the emphasis is strongly upon drugs that are either on the market, or will be on the market within the time frame of this study.

In addition to profiling drugs and explaining the mechanism by which these drugs achieve their efficacy, the report breaks out the major medical markets for immune disease. This report does not cover drugs in pre–clinical testing in detail – even though some of the drugs with novel approaches are mentioned in the appropriate sections of the report. The report does not cover drugs that act to enhance the activity of the immune system against diseases such as cancer or opportunistic infections. Even though mechanisms of certain drugs help in the treatment of various cancer indications as well as immune diseases and are indicated for both, sales to those cancer–related indications are excluded as much as possible. Another therapeutic area that is excluded is Type–1 diabetes, though it is indeed an immune disease. This is excluded because most of the drugs are commonly used for both types of diabetes, and it is difficult to get an accurate idea about the sales exclusively for managing Type–1. Additionally, medical devices, or the direct costs of surgery to treat immune diseases, etc., are not covered. We believe that the market dynamics of these products and services are dramatically different than the pharmaceutical market and need to be dealt with as a separate report. 

In general, this report contains:

An overview of the background science of the immune system, classifications of various molecules involved in immune responses, and types of immune responses

Detailed discussion of various technology types used to contain undesirable immune responses and drugs in each category

Global sales projections through 2015 for various technology types and immune disease categories

Key players in the market and their market shares

Analysis of the key challenges of the immune disease sector and its influence in the growth of the field

A discussion of specific immune diseases and their therapies 

Technology trends and patent analysis

In–depth analysis of leading companies and their successful strategies. 

INFORMATION SOURCES AND METHODOLOGY

The base year of this study is 2010. The market size reflects the global revenues of drugs estimated based on the market trends in the first 3 quarters of 2010. Generic drugs are not included in the study. Market figures are based on revenues at the manufacturer level and are projected at 2010 dollar values (inflation is not computed into the projection figures). Forecasts are largely based on the projections of the marketers. Growth of competing drugs, patient population, patent status, and lifecycle management strategies adopted by marketers have also been considered for estimating future growth trends.

The information and data to prepare this study were derived from regulatory agencies, trade literature, patient support groups, annual reports of companies and industry–related databases. The analyses presented are based on an extensive survey of the pharmaceutical industry as well as a detailed examination of published literature and reports obtained from regulatory authorities, medical research institutions, and national and world health organizations. Key information from the literature was used to obtain expert opinion and insights on commercial potential and market sizes from industry professionals, academic researchers, and government agency spokespersons. 

Chapter- 1: INTRODUCTION

STUDY GOAL AND OBJECTIVES 1

REASONS FOR DOING THE STUDY 1

INTENDED AUDIENCE 2

SCOPE OF REPORT 2

INFORMATION SOURCES AND METHODOLOGY 3

AUTHOR'S CREDENTIALS 4

RELATED BCC REPORTS 4

BCC ONLINE SERVICES 4

DISCLAIMER 5

Chapter-2: SUMMARY

SUMMARY TABLE GLOBAL SALES OF DRUGS FOR IMMUNE DISEASES, THROUGH 2015 ($ MILLIONS) 7

SUMMARY FIGURE GLOBAL MARKET FOR DRUGS TO TREAT IMMUNE DISEASES, 2009-2015 ($ MILLIONS) 7

Chapter-3: OVERVIEW

IMMUNE SYSTEM BACKGROUND 8

INNATE (NATURAL) IMMUNITY 8

Neutrophils 8

Eosinophils 9

Basophils 9

Mononuclear Cells 9

The Complement System – An Effector Component of an Immune Response 10

ACQUIRED (ADAPTIVE) IMMUNITY 11

T Cells 11

Th Cells (CD4+ T Cells) 12

Tc Cells (CD8+ T Cells) 12

B Cells 13

Null Cells (Natural Killer Cells) 13

TABLE 1   CELLS OF THE ADAPTIVE IMMUNE SYSTEM AND THEIR FUNCTION 14

HOW THE BODY RECOGNIZES "SELF" 14

HOW THE BODY PREVENTS AUTOIMMUNE DISEASES 15

THE PROBLEM OF REDUNDANCY AND COMPLEXITY 15

TYPES OF IMMUNE DISEASES 16

TABLE 2   CLASSIFICATION OF IMMUNE RESPONSES LEADING TO DISEASES 16

CLASSIFICATION OF DRUGS FOR THE TREATMENT OF IMMUNE DISEASES 17

Immunomodulators 17

Symptom–Treating Drugs 18

A LOOK AT THE INDUSTRY 18

TABLE 3   KEY CHALLENGES OF THE IMMUNE DISEASES MARKET 18

EXPENSIVE BIOLOGICS ARE LEADING TO GOVERNMENT REGULATIONS TO CUT DOWN HEALTHCARE EXPENSES 19

INSURANCE COMPANIES PROMOTING THE USE OF GENERICS 19

ADVERSE REACTIONS ARE LEADING TO INTENSE SCRUTINY OF DRUGS AND LIMIT THE REACH OF DRUGS IN THE MARKET 20

IMPACT OF THE U.S. HEALTHCARE REFORM BILL 20

REGULATORY RESTRICTIONS ON LONG–ACTING BETA AGONISTS (LABA) 21

"ME–TOO" BIOLOGICS MAY CROWD THE MARKET AND LIMIT THE POTENTIAL FOR NEW THERAPIES 21

BIOSIMILARS AND BIO–BETTERS – THREATS AND OPPORTUNITIES 22

SUCCESS OF TNF–ALPHA INHIBITORS RAISE THE ENTRY BARRIERS FOR NEW TREATMENT APPROACHES 22

ATTACK ON CORE PATENTS OF BLOCKBUSTER DRUGS BY AGGRESSIVE GENERIC MANUFACTURERS IS ON THE RISE 23

THE IMMUNE DISEASES AND DISORDERS MARKET 23

TABLE 4    GLOBAL DEMAND OF DRUGS FOR IMMUNE DISEASES AND DISORDERS BY VALUE, THROUGH 2015 ($ MILLIONS) 24

TABLE 5    GLOBAL DEMAND FOR IMMUNOSUPPRESSANTS AND OTHER IMMUNOMODULATORS, BY VALUE, THROUGH 2015 ($ MILLIONS) 24

TABLE 6 GLOBAL MARKET SHARE OF IMMUNOSUPPRESSANTS IN THE IMMUNOMODULATORS MARKETS, 2009-2015 (%) 24

TABLE 7   GLOBAL MARKET SHARE OF IMMUNOMODULATORS AND SYMPTOM–TREATING DRUGS IN IMMUNE DISEASE MARKETS, 2009-2015 (%) 25

FIGURE 1 GLOBAL MARKETS FOR IMMUNE DISEASES AND DISORDERS BY VALUE, 2009-2015 ($ MILLIONS) 25

REGIONAL MARKETS OF IMMUNE DISEASES AND DISORDERS 25

TABLE 8 U.S. DEMAND OF DRUGS FOR IMMUNE DISEASES AND DISORDERS BY VALUE, THROUGH 2015 ($ MILLIONS) 26

TABLE 9 U.S. DEMAND FOR IMMUNOMODULATORS, BY VALUE, THROUGH 2015 ($ MILLIONS) 26

TABLE 10 U.S. MARKET SHARE OF IMMUNOSUPPRESSANTS IN THE IMMUNOMODULATORS MARKETS, 2009-2015 (%) 26

TABLE 11   U.S. MARKET SHARES OF IMMUNOMODULATORS AND SYMPTOM–TREATING DRUGS IN IMMUNE DISEASE MARKETS, 2009-2015 (%) 27

FIGURE 2 U.S. MARKETS FOR IMMUNE DISEASES AND DISORDERS BY VALUE, 2009-2015 ($ MILLIONS) 27

TABLE 12 ROW DEMAND FOR DRUGS FOR IMMUNE DISEASES AND DISORDERS, BY VALUE, THROUGH 2015 ($ MILLIONS) 28

TABLE 13    ROW DEMAND FOR IMMUNOMODULATORS, BY VALUE, THROUGH 2015 ($ MILLIONS) 28

TABLE 14 ROW MARKET SHARE OF IMMUNOSUPPRESSANTS IN THE IMMUNOMODULATORS MARKETS, 2009-2015 (%) 28

TABLE 15 ROW MARKET SHARE OF IMMUNOMODULATORS AND SYMPTOM-TREATING DRUGS IN IMMUNE DISEASE MARKETS, 2009-2015 (%) 29

FIGURE 3   ROW MARKETS FOR IMMUNE DISEASES AND DISORDERS BY VALUE, 2009-2015 ($ MILLIONS) 29

FIGURE 4 REGIONAL MARKET SIZE OF DRUGS FOR IMMUNE DISEASES AND THEIR FUTURE GROWTH TRENDS, 2009-2015 30

($ MILLIONS) 30

MARKET SHARE BY TECHNOLOGY TYPES 30

TABLE 16 GLOBAL IMMUNE DISEASES AND DISORDERS MARKETS BASED ON TECHNOLOGY TYPES, BY VALUE, THROUGH 2015 ($ MILLIONS) 31

THE RISING MARKET SHARE OF BIOLOGICS 31

TABLE 17   MARKET SHARE OF BIOLOGICS IN THE GLOBAL IMMUNE DISEASES MARKETS, BY VALUE, THROUGH 2015 ($ MILLIONS) 32

TABLE 18 TOP 10 DRUGS IN THE IMMUNE DISEASE MARKETS, WORLDWIDE, 2010 (%) 32

TABLE 19 REVENUE AND MARKET SHARES OF MONOCLONAL ANTIBODIES, IMMUNE DISEASE MARKETS, THROUGH 2015 (%) 33

TOP COMPANIES BY SALES IN THE IMMUNE DISEASE MARKETS 33

TABLE 20 MARKET SHARES OF TOP 10 PLAYERS OF GLOBAL IMMUNE DISEASES MARKETS, 2010 (%) 33

BIOLOGICAL RESPONSE MODIFIERS (BRMS) CONTINUES AS A STRONG SECTOR IN THE IMMUNE DISEASE MARKETS 34

TABLE 21 MARKET SIZE OF KEY DRUGS THAT CAN BE CATEGORIZED AS BRMS IN THE IMMUNE DISEASE MARKETS, THROUGH 2015 ($ MILLIONS) 34

PAY–TO–DELAY GENERICS – AN EMERGING TREND? 34

MARKET SHARE OF COMBINATION DRUGS IS INCREASING 35

TABLE 22 SUCCESSFUL COMBINATION DRUG BRANDS AND PIPELINE PRODUCTS IN THE IMMUNE DISEASE MARKETS 35

TABLE 23 MARKET SIZE OF COMBINATION DRUGS, THROUGH 2015 ($ MILLIONS/%) 36

Chapter-4: IMMUNOMODULATORS

IMMUNOSUPPRESSANTS 37

TABLE 24 GLOBAL MARKET FOR IMMUNOSUPPRESSANTS TO TREAT IMMUNE DISEASES, THROUGH 2015 ($ MILLIONS) 38

CORTICOSTEROIDS 38

TABLE 25 SALES OF CORTICOSTEROID BRANDS AND SUPPLIERS, 2010 ($ MILLIONS) 39

COMBINATION DRUGS OF CORTICOSTEROIDS WITH OTHER CLASSES 40

TABLE 26 SALES OF TOP BRANDS OF ICS/LABA COMBINATION DRUGS AND SUPPLIERS, 2010 ($ MILLIONS) 40

LEUKOTRIENE ANTAGONISTS 40

TABLE 27 SALES OF LEUKOTRIENE ANTAGONIST BRANDS AND SUPPLIERS, 2010 ($ MILLIONS) 41

TNF–ALPHA ANTAGONISTS 41

TABLE 28   SALES OF KEY TNF–ALPHA ANTAGONIST BRANDS AND SUPPLIERS, 2010 ($ MILLIONS) 42

IMMUNOPHILIN BINDING DRUGS 43

TABLE 29 SALES OF KEY IMMUNOPHILIN INHIBITOR BRANDS AND SUPPLIERS, 2010 ($ MILLIONS) 44

INOSINE MONOPHOSPHATE DEHYDROGENASE (IMPDH) ANTAGONISTS 44

TABLE 30   SALES OF KEY INOSINE MONOPHOSPHATE DEHYDROGENASE (IMPDH) ANTAGOSISTS AND SUPPLIERS, 2010 ($ MILLIONS) 45

CD20 ANTAGONISTS 45

TABLE 31 SALES OF CD20 ANTAGONISTS AND SUPPLIERS, 2010 ($ MILLIONS) 45

B CELL–TARGETED THERAPEUTICS 46

ALPHA 4 INTEGRIN INHIBITOR 46

TABLE 32 SALES OF ALPHA 4 INTEGRIN ANTAGONISTS AND SUPPLIERS, 2010 ($ MILLIONS) 47

IGE ANTAGONISTS 47

TABLE 33   SALES OF ALPHA 4 INTEGRIN ANTAGONISTS AND SUPPLIERS, 2010 ($ MILLIONS) 48

COMPLEMENT ANTAGONISTS 48

TABLE 34 SALES OF COMPLEMENT ANTAGONISTS AND SUPPLIERS, 2010 ($ MILLIONS) 48

MISCELLANEOUS 49

TABLE 35 SALES OF MISCELLANEOUS IMMUNOSUPPRESSANTS AND SUPPLIERS, 2010 ($ MILLIONS) 49

IL–1 Antagonists 49

IL–2 Antagonists 50

IL–4 Antagonists 50

IL–5 Antagonists 51

IL–6 Antagonists 51

IL–12/IL–23 Antagonists 52

Anti–Thymocyte Globulin 52

TABLE 36 FACTORS THAT WILL IMPACT THE FUTURE MARKET SHARE OF THYMOGLOBULIN 52

CD2 Antagonists 53

CD3 Antagonists 53

CD4 Antagonists 53

CD54 Antagonists 54

CD147 Antagonists 54

B7 Antagonist– CTLA4 55

Phosphodiesterase Type IV Antagonists 55

Sphingosine 1 – Phosphate Receptor Agonist 56

Adenosine Deaminase 56

Alkylating Agents 56

Anti–Folates 56

Anti–Metabolites 57

Antibiotic Immunosuppressants 58

Antimalarial Drugs 58

Chemokine Antagonists 58

Gold Compounds 58

P38 Kinase Antagonists 59

Selectin Antagonists 59

OTHER IMMUNOMODULATORS 59

TABLE 37 GLOBAL MARKET FOR OTHER IMMUNOMODULATORS TO TREAT IMMUNE DISEASES, THROUGH 2015 ($ MILLIONS) 60

BETA INTERFERONS 60

TABLE 38 SALES OF BETA INTERFERONS AND SUPPLIERS, 2010 ($ MILLIONS) 61

DOUBLE–STRANDED DNA 61

IL–10 62

PEPTIDE FRAGMENTS 62

TABLE 39 SALES OF PEPTIDE FRAGMENTS AS IMMUNOMODULATORS AND SUPPLIERS, 2010 ($ MILLIONS) 63

Chapter-5: DRUGS TO TREAT SYMPTOMS OF IMMUNE DISEASE

DRUGS TO TREAT SYMPTOMS OF IMMUNE DISEASE 64

TABLE 40   GLOBAL MARKET FOR SYMPTOM–TREATING DRUGS TO TREAT IMMUNE DISEASES, THROUGH 2015 ($ MILLIONS) 65

H1 BLOCKERS 65

TABLE 41 SALES OF H1 RECEPTOR BLOCKER BRANDS AND THEIR SUPPLIERS, 2010 ($ MILLIONS) 65

BETA AGONISTS 66

TABLE 42 ALES OF KEY BETA AGONIST BRANDS AND THEIR SUPPLIERS, 2010 ($ MILLIONS) 67

NSAIDS (COX INHIBITORS) 67

NITRIC OXIDE–RELEASING NSAIDS 68

TABLE 43 SALES OF KEY NSAID BRANDS AND THEIR SUPPLIERS, 2010 ($ MILLIONS) 68

OTHER SYMPTOM–TREATING DRUGS IN THE IMMUNE DISEASE MARKETS 69

TABLE 44 SALES OF OTHER CLASSES OF SYMTOM–TREATING DRUG BRANDS AND THEIR SUPPLIERS, 2010 ($ MILLIONS) 69

SYNTHETIC THYROID HORMONE 69

AMINOSALICYLATES 70

RETINOIDS 70

THROMBOXANE A2 ANTAGONISTS 70

VITAMIN D DERIVATIVES 71

MUSCARINIC BLOCKERS 71

CHOLINESTERASE INHIBITORS 71

Chapter-6: TECHNOLOGY TRENDS AND PATENT ANALYSIS

TABLE 45 NUMBER OF HITS RECEIVED IN THE DATABASE SEARCH FOR PATENT APPLICATIONS FILED WITH U.S. PTO FOR VARIOUS TECHNOLOGY AREAS, 2001-2010 72

TABLE 45 (CONTINUED) 73

TABLE 46 NUMBER OF HITS RECEIVED IN THE PATENTS DATABASE OF U.S. PTO BETWEEN 2001 AND 2010 FOR SELECTED MOLECULES 74

TABLE 47 PROMISING DRUGS FOR THE TREATMENT OF IMMUNE DISEASES LAUNCHED RECENTLY/ADVANCED STAGES OF DEVELOPMENT 75

FIRST ORAL PDE–IV INHIBITOR ENTERS THE MARKET 75

THE SCOPE OF IL–12/IL–23 INHIBITORS FOR PSORIASIS 76

TABLE 48 DRIVERS AND RESTRAINTS OF IL–12/IL–23 INHIBITORS AS A NEW CLASS OF DRUGS FOR IMMUNE DISEASES 77

JAK3 ANTAGONISTS AS HIGHLY SELECTIVE IMMUNOSUPPRESSANTS 77

S1PR1 INHIBITORS 78

TABLE 49 DRIVERS AND RESTRAINTS OF S1PR1 INHIBITORS AS A NEW CLASS OF DRUGS FOR IMMUNE DISEASES 78

Chapter-7: COMMON IMMUNE DISEASES AND THEIR THERAPIES

TABLE 50 PREVALENCE OF COMMON IMMUNE DISEASES 79

TABLE 51    GLOBAL MARKET SIZE OF VARIOUS CATEGORIES OF IMMUNE DISEASES, THROUGH 2015 ($ MILLIONS) 80

RESPIRATORY DISEASES 80

ASTHMA 80

Asthma (Continued) 81

ALLERGIC RHINITIS 82

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) 82

MARKET SCENARIO OF THE TREATMENT FOR RESPIRATORY DISEASES 83

TABLE 52 COMMON BRANDS USED FOR THE TREATMENT OF ASTHMA, ALLERGIC RHINITIS AND COPD 84

TABLE 53 SALES OF KEY BRANDS USED FOR THE TREATMENT OF RESPIRATORY DISEASES IN 2010 AND THEIR SUPPLIERS ($ MILLIONS) 85

TABLE 54   GLOBAL MARKET FOR IMMUNOMODULATORS AND SYMPTOM –TREATING DRUGS TO TREAT RESPIRATORY DISEASES, THROUGH 2015 ($ MILLIONS) 85

RHEUMATOID ARTHRITIS (RA) 86

RHEUMATOID ARTHRITIS (RA) (CONTINUED) 87

RHEUMATOID ARTHRITIS (RA) (CONTINUED) 88

RHEUMATOID ARTHRITIS (RA) (CONTINUED) 89

TABLE 55 COMMON BRANDS USED FOR THE TREATMENT OF RHEUMATOID ARTHRITIS 90

PSORIASIS/PSORIATIC ARTHRITIS 90

PSORIASIS/PSORIATIC ARTHRITIS (CONTINUED) 91

TABLE 56   DRIVERS AND RESTRAINTS FOR STELARA IN PSORIASIS MARKET 92

TABLES 57 KEY BRANDS USED FOR THE TREATMENT OF RHEUMATOID ARTHRITIS, PSORIASIS, AND PSORIATIC ARTHRITIS AND THEIR SUPPLIERS 93

TABLE 58   GLOBAL MARKET FOR IMMUNOMODULATORS AND SYMPTOM –TREATING DRUGS TO TREAT AUTOIMMUNE DISEASES AFFECTING JOINTS AND SKIN*, THROUGH 2015 ($ MILLIONS) 94

CROHN'S DISEASE AND ULCERATIVE COLITIS (INFLAMMATORY BOWEL DISEASES) 94

CROHN'S DISEASE AND ULCERATIVE …(CONTINUED) 95

TABLES 59 KEY BRANDS USED FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES AND THEIR SUPPLIERS 96

TABLE 60 GLOBAL MARKET FOR IMMUNOMODULATORS AND SYMPTOM –TREATING DRUG BRANDS TO TREAT INFLAMMATORY BOWEL DISEASES*, THROUGH 2015 ($ MILLIONS) 96

MULTIPLE SCLEROSIS 97

MULTIPLE SCLEROSIS (CONTINUED) 98

TABLE 61 KEY BRANDS USED FOR THE TREATMENT OF MULTIPLE SCLEROSIS AND THEIR SUPPLIERS 99

TABLE 62 COMPARISON OF MAJOR DRUGS IN THE MS MARKET, 2010 ($ MILLIONS) 99

TABLE 62 (CONTINUED) 100

TABLE 63 GLOBAL MARKET FOR IMMUNOMODULATORS TO TREAT MULTIPLE SCLEROSIS, THROUGH 2015 ($ MILLIONS) 101

TRANSPLANT REJECTION AND GRAFT VS. HOST DISEASE (GVHD) 101

TABLE 64 KEY IMMUNOMODULATOR BRANDS IN THE TRANSPLANT REJECTION MARKETS* 102

TABLE 65 GLOBAL MARKET FOR IMMUNOMODULATORS FOR TRANSPLANT REJECTION AND GRAFT VS. HOST DISEASE, THROUGH 2015 ($ MILLIONS) 103

TABLE 66 NOVEL IMMUNOSUPPRESSANTS UNDER DEVELOPMENT FOR TRANSPLANT REJECTION AND GVHD 104

INNOVATIVE APPROACHES IN TRANSPLANTATION MARKETS– BUT IS THE MARKET READY? 105

SYSTEMIC LUPUS ERYTHEMATOSUS 106

SYSTEMIC LUPUS ERYTHEMATOSUS (CONTINUED) 107

MYASTHENIA GRAVIS 108

HASHIMOTO'S THYROIDITIS 109

TABLE 67   GLOBAL MARKET FOR THE DRUGS USED FOR THE TREATMENT OF HASHIMOTO'S DISEASE, THROUGH 2015 ($ MILLIONS) 109

SCLERODERMA 110

ANKYLOSING SPONDILITIS 111

TABLE 68   GLOBAL MARKET FOR THE DRUGS USED FOR THE TREATMENT OF ANKYLOSING SPONYLITIS, THROUGH 2015 ($ MILLIONS) 112

Chapter-8: COMPANY PROFILES

ABBOTT LABORATORIES 113

ALEXION PHARMACEUTICALS, INC. 113

AMGEN, INC. 114

APT PHARMACEUTICALS, INC. 115

ASTELLAS PHARMA 116

ASTRA ZENECA PLC 116

ATLANTIC HEALTHCARE LTD. 117

BAYER SCHERING PHARMA AG 118

BIOGEN IDEC, INC. 118

BRISTOL–MYERS SQUIBB 119

BOEHRINGER INGELHEIM GMBH 120

CELLDEX THERAPEUTICS, INC. 121

CEPHALON, INC. 122

F. HOFFMANN–LA ROCHE, LTD 122

GENZYME CORPORATION 123

GLAXO SMITHKLINE PLC 124

JOHNSON & JOHNSON 125

MERCK & CO, INC. 126

NOVARTIS INTERNATIONAL AG 127

OSIRIS THERAPEUTICS, INC. 128

PFIZER, INC. 129

PFIZER, INC. (CONTINUED) 130

PFIZER, INC. (CONTINUED) 131

Chapter-9: GLOSSARY

GLOSSARY 132

To order this report:

: Therapeutics for Immune System Disorders

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Reportlinker Adds Process Analytical Technologies for Pharmaceuticals: Global Markets
2. Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets
3. Reportlinker Adds Global Vitamins Industry
4. Reportlinker Adds US Medical Adhesives And Sealants Industry
5. Reportlinker Adds Global Microscopes Industry
6. Reportlinker Adds Global Imaging Agents Industry
7. Reportlinker Adds Global Stethoscopes Industry
8. Reportlinker Adds Global Micro-Electromechanical Systems (MEMs) Devices Industry
9. Reportlinker Adds U.K. Market for Dental Prosthetics and CAD/CAM Devices 2011
10. Reportlinker Adds Global Cardiac Monitoring Systems Market -2013
11. Reportlinker Adds Medical Devices Market in Europe 2008-2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 The vast ... an outpatient dialysis facility.  Treatments are usually 3 times ... hours per visit, including travel time, equipment preparation and ... patient, but especially grueling for patients who are elderly ... a skilled nursing and rehabilitation centers for some duration ...
(Date:6/23/2016)... Tenn. , June 23, 2016 /PRNewswire/ ... automating, integrating and transforming the patient payment ... of several innovative new products and services ... of its revenue cycle offerings. These award-winning ... more efficient workflows, remain compliant in an ...
(Date:6/23/2016)... -- The National Pharmaceutical Council (NPC) today announced that ... organization as its newest member.  ... and chief scientific officer, Mallinckrodt Pharmaceuticals, will serve ... of Directors. ... in support of our efforts to conduct research ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from PsychTests.com reveals that behind the tendency to set low expectations ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Living, is proud to recognize Dr. Barry M. Weintraub as a prominent plastic ... most beautiful women in the world, and the most handsome men, look naturally ...
Breaking Medicine News(10 mins):